Your session is about to expire
← Back to Search
Immunotoxin
SL-401 for Chronic Myelomonocytic Leukemia
Phase 2
Waitlist Available
Research Sponsored by Stemline Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through 12 months post last dose of tagraxofusp
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug, tagraxofusp, to see if it is safe and effective in treating patients with either chronic myelomonocytic leukemia or myelofibrosis who have not responded to other treatments.
Eligible Conditions
- Chronic Myelomonocytic Leukemia
- Myelofibrosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through 12 months post last dose of tagraxofusp
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through 12 months post last dose of tagraxofusp
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Evaluation of rate of response
Rate and severity of treatment-emergent adverse events
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Tagraxofusp (SL-401)Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SL-401
2014
Completed Phase 2
~90
Find a Location
Who is running the clinical trial?
Stemline Therapeutics, Inc.Lead Sponsor
23 Previous Clinical Trials
6,425 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger